Spirochromanone Cst-17 as a potent microtubule destabilizing agent showing anticancer effects in HeLa cells by binding to tubulin
Future Medicinal Chemistry · 2026
DOI: 10.1080/17568919.2026.2628554 ↗Kurz gefasst
Fachartikel in der Zeitschrift Future Medicinal Chemistry, 2026. Verfasst von Ranita Roy und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotechnology and Dr. B. C. Guha Centre for Genetic Engineering and Biotechnology, University of Calcutta, Kolkata, India. Hauptthemen laut MEDLINE: Tubulin, Antineoplastic Agents, Microtubules, Tubulin Modulators. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Council of Scientific and Industrial Research (CSIR) Government of India, Anusandhan National Research Foundation, New Delhi, DST- FIST, New Delhi.
Abstract (Originalsprache)
AIM: To unravel the cytotoxic behavior of spirochromanone against the HeLa cell line and to evaluate its potential as a microtubule-targeting agent (MTA). MATERIALS AND METHODS: 21 synthetic analogues of spiro[chroman-2,4'-piperidin]-4-one hydrochloride were screened for their cytotoxic effect on human cervical carcinoma cell line (HeLa), lung adenocarcinoma cell line (A549), and human embryonic kidney cell line (HEK-293). For cellular experiments, HeLa cells was used and tubulin interaction studies were conducted using tissue purified tubulin. An in silico assay was done for binding site determination, and ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) analysis was performed to evaluate the drug-likeness. RESULTS: Among the 21 synthetic compounds, Cst-17 showed potential anticancer effect. Cst-17 had nearly equal cytotoxicity against both HeLa and A549 cells (IC50 values of 9.03 ± 1.13 µM and 9.33 ± 0.60 µM, respectively). It disrupted the interphase microtubule network, arrested HeLa cells at G2/M phase, altered mitochondrial membrane potential (MMP) and induced caspase-dependent apoptosis. Cst-17 triggered microtubule destabilization (IC50 ~ 16 ± 4 µM) on binding near the colchicine-binding site (Kd = 10.98 ± 1.32 μM). ADMET analysis revealed the promising pharmacokinetic properties of Cst-17. CONCLUSION: Cst-17 is a potential MTA that triggers apoptosis by arresting HeLa cells at G2/M phase.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biotechnology and Dr. B. C. Guha Centre for Genetic Engineering and Biotechnology, University of Calcutta, Kolkata, India.
- Chemistry Department, BITS Pilani, Hyderabad, India.
- Guru Nanak Institute of Pharmaceutical Science & Technology, Kolkata, India.
- Cancer Research Lab, Department of Zoology, University of Calcutta, Kolkata, India.
ORCID-Profile: Gopal Chakrabarti
Förderung
- Council of Scientific and Industrial Research (CSIR) Government of India
- Anusandhan National Research Foundation, New Delhi
- DST- FIST, New Delhi
Zitieren
APA
Roy, R., Nandikolla, A., Ghosh Dastidar, D., Chatterji, U., Sekhar, K. V. G. C., & Chakrabarti, G. (2026). Spirochromanone Cst-17 as a potent microtubule destabilizing agent showing anticancer effects in HeLa cells by binding to tubulin. Future Medicinal Chemistry. https://doi.org/10.1080/17568919.2026.2628554
Vancouver
Roy R, Nandikolla A, Ghosh Dastidar D, Chatterji U, Sekhar KVGC, Chakrabarti G. Spirochromanone Cst-17 as a potent microtubule destabilizing agent showing anticancer effects in HeLa cells by binding to tubulin. Future Medicinal Chemistry. 2026. doi:10.1080/17568919.2026.2628554
BibTeX
@article{Roy2026,
author = {Roy, Ranita and Nandikolla, Adinarayana and Ghosh Dastidar, Debabrata and Chatterji, Urmi and Sekhar, Kondapalli Venkata Gowri Chandra and Chakrabarti, Gopal},
title = {Spirochromanone Cst-17 as a potent microtubule destabilizing agent showing anticancer effects in HeLa cells by binding to tubulin},
journal = {Future Medicinal Chemistry},
year = {2026},
doi = {10.1080/17568919.2026.2628554}
}
EUVIMED